AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Abverkauf von institutionellen Investoren vor Jahresende um Steuern zu optimieren. Nutze diese Gelegenheit um mit einer kleinen Tranche noch weitere Shares zu akkumulieren.

Important Update ASPR pauses allocation of bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV December 23, 2021 The Assistant Secretary for Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services are committed to ensuring timely and transparent communication regarding the monoclonal antibody therapies that are currently authorized for emergency use in response to the COVID-19 pandemic. Circulating SARS-CoV-2 viral variants, including Omicron, may be associated with resistance to monoclonal antibodies. Health care providers should review the Antiviral Resistance information in the Healthcare Provider Fact Sheet for each authorized therapeutic for details regarding specific variants and resistance. The Centers for Disease Control and Prevention (CDC) publishes information about circulating variants in the United States by region. The frequency of the Omicron variant is increasing throughout the U.S. and health care providers should refer to these frequency data as they choose a therapeutic option for their patients. FDA updated the Health Care Provider Fact Sheets for bamlanivimab and etesevimab administered together, REGEN-COV, and sotrovimab with specific information regarding expected activity against the Omicron variant (B.1.1.529/BA.1). These data show that it is unlikely that bamlanivimab and etesevimab administered together or REGEN-COV will retain activity against this variant. Based on similar cell culture data currently available, sotrovimab appears to retain activity against the Omicron variant. Based on this information, ASPR will pause any further allocations of bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV pending updated data from the CDC. Shipments of sotrovimab did resume this week, and delivery of 55,000 doses of product has begun. An additional 300,000 doses of sotrovimab will be available for distribution in January. The situation varies in different geographic regions and different health care facilities, and there may be circumstances, such as lower frequency of Omicron in a region and limited supply of alternative treatment options, in which the use of existing site supply of these therapeutics is clinically appropriate. We are working to make available the most updated information to health care providers and provide them with appropriate flexibility to provide the best care for their patients. As additional data become available, we will provide updates and further recommendations and consider if additional actions are warranted. ASPR and FDA will continue to work with the CDC and the National Institutes of Health on surveillance of variants that may impact the use of the monoclonal antibody therapies authorized for emergency use. We will provide further updates and consider additional action as new information becomes available. Information on the authorized products for the treatment of mild-to-moderate coronavirus and other authorized products for treatment or prevention of COVID 19 are available on FDA’s Emergency Use Authorization Drugs and Non-Vaccine Biological Products webpage. https://www.phe.gov/emergency/events/COVID19/therapeutics/update-23Dec2021/Pages/default.aspx?utm_campaign=Coronavirus+%28COVID-19%29+Update%3A+December+23%2C+2021&utm_medium=email&utm_source=govdelivery

Dec 21, 2021, 01:47 PM Bloom Burton Initiates a Buy Rating on AbCellera Biologics (ABCL) AbCellera Biologics (ABCL – Research Report) received a Buy rating and a $35.00 price target from Bloom Burton analyst Antonia Borovina on December 19. The company’s shares closed last Monday at $14.60, close to its 52-week low of $12.20. According to TipRanks.com, Borovina is ranked #3936 out of 7739 analysts. The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $33.60 average price target, which is a 130.5% upside from current levels. In a report released today, Benchmark Co. also initiated coverage with a Buy rating on the stock with a $27.00 price target. See the top stocks recommended by analysts >> Based on AbCellera Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $5.51 million and GAAP net loss of $21.38 million. In comparison, last year the company earned revenue of $9.36 million and had a GAAP net loss of $2.69 million. Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ABCL in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases. https://www.tipranks.com/news/blurbs/bloom-burton-initiates-a-buy-rating-on-abcellera-biologics-abcl/

https://www.marketscreener.com/quote/stock/ABCELLERA-BIOLOGICS-INC-116373768/news/Benchmark-Starts-AbCellera-Biologics-at-Buy-With-27-Price-Target-37384569/

$ABCL Benchmark-Analyst Robert Wasserman: Die monoklonale Antikörper-Entdeckungstechnologie von AbCellera hat mit Partner Eli Lilly (LLY) eines der bisher führenden COVID-19-Therapeutika produziert, aber das Unternehmen verfügt über eine Fülle zusätzlicher Partnerschaftsprogramme, Technologieplattformen und potenzieller "Shots on Goal", um ihren nächsten Erfolg und zukünftiges Wachstum sicherzustellen, teilt Wasserman den Investoren in einer Research-Mitteilung mit.

The new two-building campus provides AbCellera with ample room to grow, potentially adding as many as 1,000 employees by 2028. 

https://dailyhive.com/vancouver/abcellera-vancouver-headquarters-campus-110-150-west-4th-avenue

https://www.youtube.com/watch?v=xtuYZxdieLc

Muss mind. bei 30 sein. 500 % Wachstum. 500 %? Jep weil 5 Moleküle in der Studie sind. Zusätzlich Covid 1404. Sicherer Hafen in meinen Augen. Vorgestern nochmal aufgestockt. Erwarte mir langfristig mind. 5x.

Zwei Tranchen hab ich noch. EK 15€. Long run weiß ich wohin die Reise geht.

Es scheint, als ob es wirklich den ersten Volltreffer gibt: https://www.precisionvaccinations.com/vaccines/bebtelovimab-ly-cov1404-monoclonal-antibody

Aus dem Stocktwits Forum: Das von $ABCL und $LLY entwickelte $ABCL-Medikament 1404 neutralisiert sowohl die Delta- als auch die Omicron-Variante, die wahrscheinlich sehr bald eine Notfallgenehmigung erhalten wird.

Zack, im Plus. Bald geht's richtig los 😍

Bei 8 Euro kauf ich nach

Zeit für die Aktivierung weiterer Körbchen mit Maß zur Aufstockung.......Durchschnittspreis muss auf 12 gedrückt werden....